{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:58:10Z","timestamp":1790909890385,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-023-02003-9","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T18:18:02Z","timestamp":1673288282000},"page":"855-867","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0478-4848","authenticated-orcid":false,"given":"R.","family":"Pelluri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kongara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. R.","family":"Nagasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mahadevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Chimakurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"2003_CR1","first-page":"546","volume":"20","author":"A Chawla","year":"2018","unstructured":"Chawla A, Chawla R, Jaggi S (2018) Microvascular and macrovascular complications in diabetes mellitus: distinct or continuum? Recent Adv Diabetes 20 (4):546","journal-title":"Recent Adv Diabetes"},{"key":"2003_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.13129","volume":"20","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Meier JJ (2018) Incretin hormones: their role in health and disease. Diabetes Obes Metab 20:5\u201321","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2003_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2174\/138945009787122860","volume":"10","author":"R Gupta","year":"2009","unstructured":"Gupta R, Walunj SS, Tokala RK, Parsa KV, Singh SK, Pal M (2009) Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of type 2 diabetes. Curr Drug Targets 10(1):71\u201387","journal-title":"Curr Drug Targets"},{"issue":"3","key":"2003_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1046\/j.1365-3083.2001.00984.x","volume":"54","author":"MD Gorrell","year":"2001","unstructured":"Gorrell MD, Gysbers V, McCaughan GW (2001) CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 54(3):249\u2013264","journal-title":"Scand J Immunol"},{"issue":"3","key":"2003_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3132\/dvdr.2006.024","volume":"3","author":"BD Green","year":"2006","unstructured":"Green BD, Flatt PR, Bailey CJ (2006) Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes. Diab Vasc Dis Res 3(3):159\u2013165","journal-title":"Diab Vasc Dis Res"},{"issue":"7","key":"2003_CR6","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.2337\/db14-0052","volume":"63","author":"B Omar","year":"2014","unstructured":"Omar B, Ahr\u00e9n B (2014) Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. Diabetes 63(7):2196\u20132202","journal-title":"Diabetes"},{"issue":"1","key":"2003_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3810\/pgm.2009.01.1953","volume":"121","author":"N Bohannon","year":"2009","unstructured":"Bohannon N (2009) Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice. Postgrad Med 121(1):40\u201345","journal-title":"Postgrad Med"},{"issue":"2","key":"2003_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4103\/jpgm.JPGM_301_21","volume":"68","author":"D Dutta","year":"2022","unstructured":"Dutta D, Jindal R, Mehta D, Kumar M, Sharma M (2022) Efficacy and safety of hydroxychloroquine for managing glycemia in type-2 diabetes: a systematic review and meta-analysis. J Postgrad Med 68(2):85","journal-title":"J Postgrad Med"},{"issue":"1","key":"2003_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1517\/13543784.12.1.87","volume":"12","author":"DJ Drucker","year":"2003","unstructured":"Drucker DJ (2003) Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 12(1):87\u2013100","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"2003_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00125-005-0107-1","volume":"49","author":"JJ Holst","year":"2006","unstructured":"Holst JJ (2006) Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 49(2):253\u2013260","journal-title":"Diabetologia"},{"issue":"4","key":"2003_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.beem.2009.03.004","volume":"23","author":"NA Thornberry","year":"2009","unstructured":"Thornberry NA, Gallwitz B (2009) Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab 23(4):479\u2013486","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2003_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/jdi.12490","volume":"7","author":"Y Seino","year":"2016","unstructured":"Seino Y, Kuwata H, Yabe D (2016) Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. J Diabetes Investig 7:102\u2013109","journal-title":"J Diabetes Investig"},{"issue":"Supplement_2","key":"2003_CR13","doi-asserted-by":"publisher","first-page":"S258","DOI":"10.2337\/dc11-s230","volume":"34","author":"AJ Garber","year":"2011","unstructured":"Garber AJ (2011) Incretin effects on \u03b2-cell function, replication, and mass: the human perspective. Diabetes Care 34(Supplement_2):S258\u2013S263","journal-title":"Diabetes Care"},{"issue":"12","key":"2003_CR14","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/j.1463-1326.2010.01299.x","volume":"12","author":"D Gupta","year":"2010","unstructured":"Gupta D, Kono T, Evans-Molina C (2010) The role of peroxisome proliferator-activated receptor \u03b3 in pancreatic \u03b2 cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. Diabetes Obes Metab 12(12):1036\u20131047","journal-title":"Diabetes Obes Metab"},{"key":"2003_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1463-1326.2008.00969.x","volume":"10","author":"J Rahier","year":"2008","unstructured":"Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC (2008) Pancreatic \u03b2-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 10:32\u201342","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2003_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1517\/14656566.2015.1000301","volume":"16","author":"R Morishita","year":"2015","unstructured":"Morishita R, Nakagami H (2015) Teneligliptin: expectations for its pleiotropic action. Expert Opin Pharmacother 16(3):417\u2013426","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"2003_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.4093\/dmj.2017.41.5.337","volume":"41","author":"SH Ko","year":"2017","unstructured":"Ko SH, Hur KY, Rhee SY, Kim NH, Moon MK, Park SO, Lee BW, Kim HJ, Choi KM, Kim JH (2017) Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association. Diabetes Metab J 41(5):337\u2013348","journal-title":"Diabetes Metab J"},{"issue":"11","key":"2003_CR18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777\u2013784","journal-title":"Ann Intern Med"},{"issue":"9","key":"2003_CR19","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/sim.1761","volume":"23","author":"MJ Sweeting","year":"2004","unstructured":"Sweeting MJ, Sutton AJ, Lambert PC (2004) What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23(9):1351\u20131375","journal-title":"Stat Med"},{"key":"2003_CR20","volume-title":"Cochrane handbook for systematic reviews of interventions","year":"2019","unstructured":"Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2019) Cochrane handbook for systematic reviews of interventions. John Wiley & Sons, Hoboken, New Jersey, US"},{"issue":"4","key":"2003_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/jdi.13389","volume":"12","author":"L Ji","year":"2021","unstructured":"Ji L, Ma J, Lu W, Liu J, Zeng JE, Yang J, Li W, Zhang X, Xiao X, Takayanagi G, Wang Y (2021) Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. J Diabetes Investig 12(4):537\u2013545","journal-title":"J Diabetes Investig"},{"issue":"1","key":"2003_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4103\/ijem.IJEM_97_16","volume":"22","author":"P Agarwal","year":"2018","unstructured":"Agarwal P, Jindal C, Sapakal V (2018) Efficacy and safety of teneligliptin in Indian patients with inadequately controlled type 2 diabetes mellitus: a randomized, double-blind study. Indian J Endocrinol Metab 22(1):41","journal-title":"Indian J Endocrinol Metab"},{"issue":"5","key":"2003_CR23","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/dom.12631","volume":"18","author":"S Hong","year":"2016","unstructured":"Hong S, Park CY, Han KA, Chung CH, Ku BJ, Jang HC, Ahn CW, Lee MK, Moon MK, Son HS, Lee CB (2016) Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in K orean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial. Diabetes Obes Metab 18(5):528\u2013532","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2003_CR24","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/dom.12092","volume":"15","author":"T Kadowaki","year":"2013","unstructured":"Kadowaki T, Kondo K (2013) Efficacy, safety and dose\u2013response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 15(9):810\u2013818","journal-title":"Diabetes Obes Metab"},{"key":"2003_CR25","unstructured":"Monotherapy Study of MP-513 in patients with type 2 diabetes\u2014full text view\u2014ClinicalTrials.gov NCT00998881, 2014"},{"issue":"2","key":"2003_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.222","volume":"4","author":"L Ji","year":"2021","unstructured":"Ji L, Li L, Ma J, Li X, Li D, Meng B, Lu W, Sun J, Liu Y, Takayanagi G, Wang Y (2021) Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: a phase 3, randomized, double-blind, placebo-controlled study. Endocrinol Diabetes Metab 4(2):e00222","journal-title":"Endocrinol Diabetes Metab"},{"issue":"3","key":"2003_CR27","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/dom.12424","volume":"17","author":"MK Kim","year":"2015","unstructured":"Kim MK, Rhee EJ, Han KA, Woo AC, Lee MK, Ku BJ, Chung CH, Kim KA, Lee HW, Park IB, Park JY (2015) Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in K orean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial. Diabetes Obes Metab 17(3):309\u2013312","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2003_CR28","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/dom.12235","volume":"16","author":"T Kadowaki","year":"2014","unstructured":"Kadowaki T, Kondo K (2014) Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension. Diabetes Obes Metab 16(5):418\u2013425","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2003_CR29","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/jdi.12092","volume":"4","author":"T Kadowaki","year":"2013","unstructured":"Kadowaki T, Kondo K (2013) Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 4(6):576\u2013584","journal-title":"J Diabetes Investig"},{"issue":"10","key":"2003_CR30","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1080\/14656566.2016.1190334","volume":"17","author":"A Bryson","year":"2016","unstructured":"Bryson A, Jennings PE, Deak L, Paveliu FS, Lawson M (2016) The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension. Expert Opin Pharmacother 17(10):1309\u20131316","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"2003_CR31","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/dom.13079","volume":"20","author":"T Kadowaki","year":"2018","unstructured":"Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Gouda M, Iijima H, Watanabe Y (2018) Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study. Diabetes Obes Metab 20(2):453\u2013457","journal-title":"Diabetes Obes Metab"},{"issue":"13","key":"2003_CR32","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1080\/14656566.2017.1359259","volume":"18","author":"T Kadowaki","year":"2017","unstructured":"Kadowaki T, Kondo K, Sasaki N, Miyayama K, Yokota S, Terata R, Gouda M (2017) Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period. Expert Opin Pharmacother 18(13):1291\u20131300","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"2003_CR33","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/dom.14679","volume":"24","author":"M Lee","year":"2022","unstructured":"Lee M, Lee WJ, Kim JH, Lee BW (2022) Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: a multicentre, randomized, double-blind, and placebo-controlled study. Diabetes Obes Metab 24(6):1105\u20131113","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2003_CR34","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1080\/14656566.2016.1183645","volume":"17","author":"X Tan","year":"2016","unstructured":"Tan X, Hu J (2016) Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother 17(9):1285\u20131293","journal-title":"Expert Opin Pharmacother"},{"issue":"50","key":"2003_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.gde.2018.02.001","volume":"1","author":"PW Franks","year":"2018","unstructured":"Franks PW, Merino J (2018) Gene-lifestyle interplay in type 2 diabetes. Curr Opin Genet Dev 1(50):35\u201340","journal-title":"Curr Opin Genet Dev"},{"issue":"9","key":"2003_CR36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3389\/fphar.2018.00449","volume":"4","author":"X Li","year":"2018","unstructured":"Li X, Huang X, Bai C, Qin D, Cao S, Mei Q, Ye Y, Wu J (2018) Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 4(9):449","journal-title":"Front Pharmacol"},{"issue":"3","key":"2003_CR37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/1753-0407.12196","volume":"7","author":"X Cai","year":"2015","unstructured":"Cai X, Han X, Luo Y et al (2015) Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on \u03b2-cell function in Asian and Caucasian type 2 diabetes mellitus patients: a meta-analysis. J Diabetes 7(3):347\u2013359","journal-title":"J Diabetes"},{"issue":"2","key":"2003_CR38","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3803\/EnM.2020.818","volume":"36","author":"D Dutta","year":"2021","unstructured":"Dutta D, Agarwal A, Maisnam I, Singla R, Khandelwal D, Sharma M (2021) Efficacy and safety of the novel dipeptidyl peptidase-4 inhibitor gemigliptin in the management of type 2 diabetes: a meta-analysis. Endocrinol Metab 36(2):374","journal-title":"Endocrinol Metab"},{"key":"2003_CR39","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JP Wilding","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MT, Wadden TA, Wharton S (2021) Once-weekly semaglutide in adults with overweight or obesity. New England J Med 384:989\u20131002","journal-title":"New England J Med"},{"issue":"1","key":"2003_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/jim-2021-002227","volume":"70","author":"R Villela","year":"2022","unstructured":"Villela R, Correa R (2022) Semaglutide 2.4 mg: the latest GLP-1RA approved for obesity. J Investig Med 70(1):3\u20134","journal-title":"J Investig Med"},{"key":"2003_CR41","first-page":"515","volume-title":"GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician? Annales dendocrinologie","author":"AJ Scheen","year":"2013","unstructured":"Scheen AJ (2013) GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician? Annales dendocrinologie, vol 74. Elsevier Masson, Amsterdam, Netherlands, pp 515\u2013522"},{"issue":"4","key":"2003_CR42","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1517\/14740338.2015.1006625","volume":"14","author":"AJ Scheen","year":"2015","unstructured":"Scheen AJ (2015) Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf 14(4):505\u2013524","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"2003_CR43","doi-asserted-by":"publisher","first-page":"434","DOI":"10.4103\/ijem.IJEM_418_20","volume":"24","author":"D Dutta","year":"2020","unstructured":"Dutta D, Bhattacharya S, Krishnamurthy A, Sharma LK, Sharma M (2020) Efficacy and safety of novel dipeptidyl-peptidase-4 inhibitor evogliptin in the management of type 2 diabetes mellitus: a meta-analysis. Indian J Endocrinol Metab 24(5):434","journal-title":"Indian J Endocrinol Metab"},{"issue":"12","key":"2003_CR44","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.2337\/dc06-0706","volume":"29","author":"B Charbonnel","year":"2006","unstructured":"Charbonnel B, Karasik A, Liu J, Wu M, Meininger G, Sitagliptin Study 020 Group (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29(12):2638\u20132643","journal-title":"Diabetes Care"},{"issue":"2","key":"2003_CR45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1463-1326.2008.00994.x","volume":"11","author":"E Ferrannini","year":"2009","unstructured":"Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahr\u00e9n B, Byiers S, Shao Q, Dejager S (2009) Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 11(2):157\u2013166","journal-title":"Diabetes Obes Metab"},{"issue":"46","key":"2003_CR46","doi-asserted-by":"publisher","first-page":"e12633","DOI":"10.1097\/MD.0000000000012633","volume":"97","author":"B Wang","year":"2018","unstructured":"Wang B, Sun Y, Sang Y, Liu X, Liang J (2018) Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: a system review and meta-analysis. Medicine 97(46):e12633","journal-title":"Medicine"},{"issue":"7","key":"2003_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236603","volume":"15","author":"M Takahashi","year":"2020","unstructured":"Takahashi M, Shibasaki M, Echizen H, Kushiyama A (2020) Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: a meta-analysis. PLoS ONE 15(7):e0236603","journal-title":"PLoS ONE"},{"key":"2003_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12456","author":"J Ba","year":"2016","unstructured":"Ba J et al (2016) Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin. J Diabetes. https:\/\/doi.org\/10.1111\/1753-0407.12456","journal-title":"J Diabetes"},{"issue":"4","key":"2003_CR49","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1177\/1470320315587180","volume":"16","author":"K Fukui","year":"2015","unstructured":"Fukui K, Kawahito H, Wakana N, Kikai M, Terada K, Yamamoto K, Irie D, Kato T, Miyagawa S, Yamada H (2015) Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic \u03b2-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers. J Ren Angiotensin Aldosterone Syst 16(4):1001\u20131009","journal-title":"J Ren Angiotensin Aldosterone Syst"},{"issue":"1","key":"2003_CR50","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.diabres.2008.10.009","volume":"83","author":"V Mohan","year":"2009","unstructured":"Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, Amatruda JM, Stein PP, Kaufman KD (2009) Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 83(1):106\u2013116","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"2003_CR51","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s40618-016-0465-1","volume":"39","author":"W Gao","year":"2016","unstructured":"Gao W, Wang Q, Yu S (2016) Efficacy, safety and impact on \u03b2-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis. J Endocrinol Invest 39(9):1061\u20131074","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2003_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep44865","volume":"7","author":"X Lyu","year":"2017","unstructured":"Lyu X, Zhu X, Zhao B, Du L, Chen D, Wang C, Liu G, Ran X (2017) Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. Sci Rep 7(1):1\u20131","journal-title":"Sci Rep"},{"issue":"10","key":"2003_CR53","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.2337\/diabetes.47.10.1643","volume":"47","author":"E Bonora","year":"1998","unstructured":"Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M (1998) Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 47(10):1643\u20131649","journal-title":"Diabetes"},{"issue":"7","key":"2003_CR54","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2337\/diacare.25.7.1135","volume":"25","author":"E Bonora","year":"2002","unstructured":"Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Cacciatori V (2002) HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the verona diabetes complications study. Diabetes Care 25(7):1135\u20131141","journal-title":"Diabetes Care"},{"key":"2003_CR55","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/j.1463-1326.2011.01380.x","volume":"13","author":"K Esposito","year":"2011","unstructured":"Esposito K, Cozzolino D, Bellastella G et al (2011) Dipeptidyl peptidase-4 inhibitors and HbA1c target of < 7 % in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 13:594\u2013603","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 2","key":"2003_CR56","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1016\/S1262-3636(08)73399-8","volume":"34","author":"A Penfornis","year":"2008","unstructured":"Penfornis A, Borot S, Raccah D (2008) Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies. Diabetes Metab 34(Suppl 2):S78\u2013S90","journal-title":"Diabetes Metab"},{"key":"2003_CR57","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jama.298.2.194","volume":"298","author":"RE Amori","year":"2007","unstructured":"Amori RE, Lau J, Pittas AG (2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298:194\u2013206","journal-title":"JAMA"},{"issue":"1","key":"2003_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40360-016-0084-7","volume":"17","author":"L He","year":"2016","unstructured":"He L, Liu S, Shan C, Tu Y, Li Z, Zhang XD (2016) Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis. BMC Pharmacol Toxicol 17(1):1\u20131","journal-title":"BMC Pharmacol Toxicol"},{"issue":"34","key":"2003_CR59","doi-asserted-by":"publisher","first-page":"e11946","DOI":"10.1097\/MD.0000000000011946","volume":"97","author":"X Wang","year":"2018","unstructured":"Wang X, Li X, Qie S, Zheng Y, Liu Y, Liu G (2018) The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: a systemic review and meta-analysis. Medicine 97(34):e11946","journal-title":"Medicine"},{"issue":"6","key":"2003_CR60","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00592-018-1271-3","volume":"56","author":"G Sesti","year":"2019","unstructured":"Sesti G, Avogaro A, Belcastro S, Bonora BM, Croci M, Daniele G, Dauriz M, Dotta F, Formichi C, Frontoni S, Invitti C (2019) Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetol 56(6):605\u2013617","journal-title":"Acta Diabetol"},{"issue":"117","key":"2003_CR61","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.diabres.2016.04.055","volume":"1","author":"JW Eriksson","year":"2016","unstructured":"Eriksson JW, Bodegard J, Nathanson D, Thuresson M, Nystr\u00f6m T, Norhammar A (2016) Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. Diabetes Res Clin Pract 1(117):39\u201347","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"2003_CR62","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/j.1463-1326.2012.01610.x","volume":"14","author":"K Goo\u00dfen","year":"2012","unstructured":"Goo\u00dfen K, Gr\u00e4ber S (2012) Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 14(12):1061\u20131072","journal-title":"Diabetes Obes Metab"},{"issue":"150","key":"2003_CR63","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.diabres.2019.02.014","volume":"1","author":"B Sinha","year":"2019","unstructured":"Sinha B, Ghosal S (2019) Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract 1(150):8\u201316","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2003_CR64","doi-asserted-by":"publisher","first-page":"128","DOI":"10.4103\/ijem.IJEM_613_18","volume":"23","author":"AK Singh","year":"2019","unstructured":"Singh AK, Singh R (2019) Heart failure hospitalization with DPP-4 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Indian J Endocrinol Metab 23(1):128","journal-title":"Indian J Endocrinol Metab"},{"issue":"1","key":"2003_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2840-12-3","volume":"12","author":"SS Engel","year":"2013","unstructured":"Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ (2013) Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol 12(1):1\u20131","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"2003_CR66","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.diabet.2018.05.007","volume":"44","author":"AJ Scheen","year":"2018","unstructured":"Scheen AJ (2018) Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: results of randomized controlled trials and observational studies. Diabetes Metab 44(5):386\u2013392","journal-title":"Diabetes Metab"},{"issue":"1","key":"2003_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-16101-1","volume":"7","author":"CY Chou","year":"2017","unstructured":"Chou CY, Chang YT, Yang JL, Wang JY, Lee TE, Wang RY, Hung CC (2017) Effect of long-term incretin-based therapies on ischemic heart diseases in patients with type 2 diabetes mellitus: a network meta-analysis. Sci Rep 7(1):1\u20133","journal-title":"Sci Rep"},{"issue":"1","key":"2003_CR68","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3803\/EnM.2020.777","volume":"36","author":"DH Seo","year":"2021","unstructured":"Seo DH, Ha KH, Kim SH, Kim DJ (2021) Effect of teneligliptin versus sulfonylurea on major adverse cardiovascular outcomes in people with type 2 diabetes mellitus: a real-world study in Korea. Endocrinol Metab 36(1):70\u201380","journal-title":"Endocrinol Metab"},{"issue":"1","key":"2003_CR69","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.diabet.2016.09.005","volume":"43","author":"MB Rehman","year":"2017","unstructured":"Rehman MB, Tudrej BV, Soustre J, Buisson M, Archambault P, Pouchain D, Vaillant-Roussel H, Gueyffier F, Faillie JL, Perault-Pochat MC, Cornu C (2017) Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab 43(1):48\u201358","journal-title":"Diabetes Metab"},{"issue":"123","key":"2003_CR70","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.diabres.2016.12.004","volume":"1","author":"T Nystr\u00f6m","year":"2017","unstructured":"Nystr\u00f6m T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW (2017) Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. Diabetes Res Clin Pract 1(123):199\u2013208","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02003-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02003-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02003-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T17:11:46Z","timestamp":1681578706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02003-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":70,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["2003"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02003-9","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"assertion":[{"value":"25 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}